

Substitute for form 1449A/PYO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	7
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	09/982,978
<b>Filing Date</b>	October 22, 2009
<b>First Named Inventor</b>	Thomas Coolidge
<b>Group Art Unit</b>	
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	P05691US1

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature

Date 10/10/20  
Considered

\*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Complete if Known	
				Application Number	09/982,978
Sheet 2 of 7		Filing Date	October 22, 2001	First Named Inventor	Thomas Coolidge
		Group Art Unit		Examiner Name	
		Attorney Docket Number	P05691US1		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	12.	GEOFFREY ALLEN and CORA A. HENWOOD, "Purification of Recombinant Epidermal Growth Factor From a Fusion Protein Expressed in Escherichia Coli; Protein Purification: Micro to Macro", 1987, Pages 367-373, Department of Protein Chemistry, Wellcome Biotech, Langley Court, Beckenham, Kent BR3 3BS, UK Alan R. Liss, Inc.,	<input type="checkbox"/>
	13.	AVIJIT LAHIRI, ROXY SENIOR and RAJ KHATTAR, "The Role of Neurohormonal Antagonists in Hibernating Myocardium", Journal of Cardiovascular Pharmacology 33 (Suppl.3):S9-S16, 1999, Lippincott Williams & Wilkins, London, Eng.	<input type="checkbox"/>
	14.	JAMES M. WILSON, M.D., "Reversible Congestive Heart Failure Caused by Myocardial Hibernation", Texas Heart Institute Journal, V. 26, No. 1, 1999, pp. 19-27, USA	<input type="checkbox"/>
	15.	G. CHAD HUGHES, M.D., ALAN P. KYPSON, M.D., JAMES D. ST. LOUIS, M.D., BRIAN H. ANNEX, M.D., R. EDWARD COLEMAN, M.D., TIMOTHY R. DEGRADO, PH.D., CAROLYN L. DONOVAN, M.D., JAMES E. LOWE, M.D. and KEVIN P. LANDOLFO, M.D.; "Improved Perfusion and Contractile Reserve After Transmyocardial Laser Revascularization in a Model of Hibernating Myocardium", 1999; 67:1714-1720 by The Society of Thoracic Surgeons, Elsevier Science Inc., USA	<input type="checkbox"/>
	16.	ARTHUR EUGENE CHIN, M.D., KATRINA HEDBERG, M.D., M.P.H., DAVID W. FLEMING, M.D.; "What is Rationing?"; The New England Journal of Medicine; July 15, 1999, Vol. 341, No. 3, pp. 213-214, The Massachusetts Medical Society, Boston, MA.	<input type="checkbox"/>
	17.	M.G. GUNNING, C. ANAGNOSTOPOULOS, G. DAVIES, C.J. KNIGHT, D.J. PENNELL, K.M. FOX, J. PEPPER and S.R. UNDERWOOD; "Simultaneous assessment of myocardial viability and function for the detection of hibernating myocardium using ECG-gated 99Tcm-tetrofosmin emission tomography: A comparison with 201 Tl emission tomography combined with cine magnetic resonance imaging", 1999, Nuclear Medicine Communications, pp. 209-214; Lippincott Williams & Wilkins	<input type="checkbox"/>
	18.	G. HOR, W.T. KRANERT, F.D. MAUL, D. SCHRODER, A. KARIMIAN-TATRIZ, O. GEB, R.P. BAUM and U.W. SCHERER, "Gated metabolic positron emission tomography (GAPET) of the myocardium: 18F-FDG-PET to optimize recognition of myocardial hibernation", 1998, Nuclear Medicine Communications, pp. 535-545, Lippincott-Raven Publishers	<input type="checkbox"/>
	19.	ROBERTO BOLLI and EDUARDO MARBAN, Molecular and Cellular Mechanisms of Myocardial Stunning", 1999, Physiological Reviews, Vol. 79, No. 2, pp. 609-634, American Physiological Society, USA	<input type="checkbox"/>
	20.	SHAHBUDIN H. RAHIMTOOLA, M.B., FRCP, MACP, "concept and Evaluation of Hibernating Myocardium", 1999, Annual Review of Medicine, pp. 75-86; Annual Reviews, USA	<input type="checkbox"/>
			<input type="checkbox"/>

Examiner Signature		Date Considered	10/28/02
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	09/982,978
		Filing Date	October 22, 2001
		First Named Inventor	Thomas Coolidge
		Group Art Unit	
		Examiner Name	
Sheet 3 of 7	Attorney Docket Number	P05691US1	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	21.	F.M. BAER AND E. ERDMANN, "Methods of Assessment and Clinical Relevance of Myocardial Hibernation and Stunning; <u>The Thoracic and Cardiovascular Surgeon</u> ; (1998) (Supplement) 264-269, Georg Thieme Verlag Stuttgart, New York, USA	
	22.	ROBERTO FERRARI, M.D., PATRIZIA PEPI, M.D., FEDERICA FERRARI, M.D., FRANCESCA NESTA, M.D., MASSIMO BENIGNO, M.D. and ODOARDO VISIOLI, M.D., "Metabolic Derangement in Ischemic Heart Disease and Its Therapeutic Control", <u>The American Journal of Cardiology</u> , 1998, Excerpta Medica	
	23.	MARGRETH B. VROOM, MD, and HARRY B. VAN WEZEL, MD, "Myocardial Stunning, Hibernation, and Ischemic Preconditioning", <u>Journal of Cardiothoracic and Vascular Anesthesia</u> , Vol. 10, No. 6 (October), 1996: pp 789-799, W.B. Saunders Company	
	24.	GERD HEUSCH and RAINER SCHULZ, "Hibernating Myocardium: A Review", <u>Journal of Molecular and Cellular Cardiology</u> , 1996, pp. 2359-2372; Academic Press Limited	
	25.	WILLIAM F. ARMSTRONG, MD, FACC, "HIBERNATING" Myocardium: Asleep or Part Dead?", <u>Journal of American College of Cardiology</u> , August, 1996, pp. 530-535, Elsevier Science Inc.	
	26.	STEVEN BURN, JOHN. L. CAPLIN, "Myocardial hibernation", <u>British Journal of Hospital Medicine</u> , 1995, Vol 53, No. 8, pp. 395-402.	
	27.	ANTONIO VITARELLI, MD, SUSANNA SCIOMER, MD, MARIA PENCO, MD, ALESSANDRA DAGIANTI, MD, and MARCO PUGLIESE, MD, "Assessment of Left Ventricular Dyssynergy by Color Kinesis", 1998, <u>The American Journal of Cardiology</u> , pp. 86G-90G, Excerpta Medica, Inc.	
	28.	PORTER PA et al.; "Nocturnal Hypoglycemia in Diabetic Children", 1997, <u>New England Journal of Medicine</u> , Individual, Inc., USA	
	29.	SHEHADEH, A., REGAN TJ, "Cardiac Consequences of Diabetes Mellitus", 1995, <u>New England Journal of Medicine</u> ; Individual, Inc., USA	
	30.	AVIJIT LAHIRI, ROXY SENIOR and RAJ KHATTAR, "The Role of Neurohormonal Antagonists in Hibernating Myocardium", 1999, <u>Journal of Cardiovascular Pharmacology</u> , pp. S9-S16, Lippincott Williams & Wilkins, London, Eng.	
	31.	DOMENICO PAGANO, MD, FRCS, ROBERT S. BONSER, MRCP, FRCS, and PAOLO G. CAMICI, MD, FRCP; "Myocardial revascularization for the treatment of post-ischemic heart failure", 1999, pp. 506-509, <u>Current Opinion In</u> , Lippincott Williams & Wilkins, London, Eng.	
	32.	J.J. BAX, MD, PHD, D. POLDERMANS, MD, PHD, F.C. VISSER, MD, PHD, A ELHENDY, MD, PHD, E BOESMA, PHD, J.H. CORNEL MD, P.M. FLORETTI, MD, PHD, and C.A. VISSER, MD; "Delayed recovery of hibernating myocardium after surgical revascularization: Implications for discrepancy between metabolic imaging and dobutamine echocardiography for assessment of myocardial viability", November/December 1999, pp. 685-687, Mosby	
Examiner Signature	Date Considered		not 10/28/02

\* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Approved for use through 10/31/2002, OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known			
		Application Number	09/982,978		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Filing Date	October 22, 2001		
		First Named Inventor	Thomas Coolidge		
		Group Art Unit			
		Examiner Name			
Sheet	4	of	7	Attorney Docket Number	P05691US1
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	33	GERRIT D. DISPERSYN, MARCEL BORGERS, WILLEM FLAMENG, "Apoptosis in chronic hibernating myocardium: sleeping to death?", <u>Cardiovascular Research</u> , 2000, pp. 696-703, Elsevier Science			
	34	D. PAGANO, J.N. TOWNEND, D.V. PARUMS, R.S. BONSER, P.G. CAMICI, "Hibernating Myocardium: morphological correlates of inotropic stimulation and glucose uptake", April, 2000, <u>Heart</u> , pp. 456-461; BMJ Publishing Group			
	35	ANDREW J. SHERMAN, FRANCIS J. KLOCKE, ROBERT S. DECKER, MARLENE L. DECKER, KAREN A. KOZLOWSKI, KATHLEEN R. HARRIS, SASCHA HEDJBELI, YURI YAROSHENKO, SAKIE NAKAMURA, MICHELE A. PARKER, PAUL A. CHECCHIA, and DANIEL B. EVANS; "Myofibrillar disruption in hypocontractile myocardium showing perfusion-contraction matches and mismatches", April 2000, pp. H1320-H1334; Vol. 278, No. 4; <u>American Journal of Physiology: The American Physiological Society</u>			
	36	LI FENG WANG, RAVICHANDRAN RAMASAMY, SAUL SCHAEFER, "Regulation of glycogen utilization in ischemic hearts after 24 hours of fasting", June, 1999; Vol. 42, No. 3; pp. 644-650, <u>Cardiovascular Research</u> , Journal of the European Society of Cardiology, Elsevier Science			
	37	JEAN-LOUIS J VANOVERSCHELDE, AGNES PASQUET, BERNHARD GERBER, JACQUES A MELIN; "Pathophysiology of myocardial hibernation. Implications for the use of dobutamine echocardiography to identify myocardial viability", 1999; <u>HEART</u> , Echocardiography, pp. III1-III7, BMJ Publishing Group			
	38	ROBERTO FERRARI, "The Search for the Hibernating Myocardium—Have We Reached the Limit?", 1999, pp. 137-143; <u>Cardiovascular Drugs And Therapy</u> ; Kluwer Academic Publishers			
	39	JOHN M. CANTY, JR., AND JAMES A. FALLAVOLLITA; "Resting myocardial flow in hibernating myocardium: validating animal models of human pathophysiology", 1999; <u>American Journal of Physiology</u> , Vol. 277, No. 1, pp. H417-H422; American Physiological Society			
	40	HOSSEIN JADVAR, PHD, MD, H. WILLIAM STRAUSS, MD, GEORGE M. SEGALL, MD; "SPECT and PET in the Evaluation of Coronary Artery Disease", July-August 1999, Vol. 19, No. 4, pp. 915-926; <u>RadioGraphics</u> , The Radiological Society of North America (RSNA)			
	41	F. FATH-ORDOUBADI, K.J. BEATT, N. SPYROU, P.G. CAMICI; "Efficacy of coronary angioplasty for the treatment of hibernating myocardium", <u>HEART</u> , August, 1999, Vol. 82, No. 2, pp. 210-216; BMJ Publishing Group			
	42	KESAVAN SHAN, MD, SHERIF F. NAGUEH, MD, and WILLIAM A. ZOGHBI, MD; "Assessment of Myocardial Viability With Stress Echocardiography", <u>Cardiology Clinics</u> , August 1999, Vol. 17, No. 3, pp. 539-553; W.B. Saunders Company, A division of Harcourt Brace & Company, Philadelphia, London, Toronto, Montreal, Sydney, Tokyo			
Examiner Signature				Date Considered	not 10/28/02

\* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Approved for use through 10/31/2002. OMB 0651-0041.  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		<b>Application Number</b>	09/982,978
		<b>Filing Date</b>	October 22, 2001
		<b>First Named Inventor</b>	Thomas Coolidge
		<b>Group Art Unit</b>	
<b>Examiner Name</b>			
<b>Sheet</b>	5	of	7
		<b>Attorney Docket Number</b>	P05691US1

<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	43.	JULIO A. PANZA, MD, VASKEN DILSIZIAN, MD, RODOLFO V. CUIEL, MD., ELLIS F. UNGER, MD, JOY M. LAURIENZO, RN, and ANASTASIA N. KITSIOU, MD; "Myocardial blood flow at rest and contractile reserve in patients with chronic coronary artery disease and left ventricular dysfunction"; <u>Journal Of Nuclear Cardiology</u> ; September/October 1999; Vol. 6, No. 5, pp. 487-494; MO	
	44.	VICTOR M. GIL; "Myocardial Viability in Ischemic Ventricular Dysfunction" <u>Portuguese Journal of Cardiology</u> , September 1999, Vol 18, Suppl IV, Portuguesa De Cardiologia; Portugal	
	45.	PAOLO G. CAMICI, MD, FESC, FACC, FRCP, ORNELLA RIMOLDI, MD, FACC; "Myocardial Hibernation vs. Repetitive Stunning in Patients"; <u>Cardiology in Review</u> ; November/1999, Vol 7, No. 1, pp. 39-43; Lippincott Williams & Wilkens	
	46.	BHARATI SH. VALKAR, MD, WILLEM FLAMENG, MD, MONIKA SZILARD, MD, SORIN PISLARU, MD, MARCEL BORGERS, PHD., JOHAN VANHAECKE, MD; "Repeated Stunning Precedes Myocardial Hibernation in Progressive Multiple Coronary Artery Obstruction"; <u>Journal of the American College of Cardiology</u> , December 1999, Vol. 34, No. 7, pp. 2126-2136; Elsevier	
	47.	A AL-MOHAMMAD, M Y NORTON, I R MAHY, J C PATEL, A E WELCH, P MIKECZ, S WALTON; "Can the surface electrocardiogram be used to predict myocardial viability?"; <u>HEART</u> , December 1999, Vol. 82, No. 6, pp. 663-667; BMJ Publishing Group	
	48.	JUCYLEA M. CWAJG, MD, EDUARDO DWAJG, MD, SHERIF F. MAGUEH, MD, FACC, ZUO-XIANG HE, MD, USMAN QURESHI, MD, FACC, LEOPOLDO I. OLMOS, MD, MIGUEL A. QUINONES, MD, FACC, MARIO S. VERANI, MD, FACC, WILLIAM L. WINTERS, MD, MACC, WILLIAM A. ZOGHBI, MD, FACC; "End-Diastolic Wall Thickness as a Predictor of Recovery of Function in Myocardial Hibernation"; <u>Journal of the American College of Cardiology</u> , April, 2000, Vol. 35, No. 5, pp. 1152-1161; Elsevier	
	49.	MICHEL ZUBER, KATHRIN GERBER, PAUL ERNE; "Myocardial tissue characterization in heart failure by real-time integrated backscatter"; <u>European Journal of Ultrasound</u> , May 1999, vol. o, No. 2, pp. 135-143; Elsevier	
	50.	CARL S. APSTEIN, MD; "Glucose-Insulin-Potassium for Acute Myocardial Infarction"; 2000; <u>Editorial</u> No. XP0000960510; Heart Association, Inc.	
<b>Examiner Signature</b>			<b>Date Considered</b> 10/28/02

\* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Form PTO/SA08B, (10-01)

Approved for use through 10/31/2002. OMB 0651-0033

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
		Application Number	09/982,978		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)		Filing Date	October 22, 2001		
		First Named Inventor	Thomas Coolidge		
		Art Unit			
		Examiner Name			
Sheet	6	of	7	Attorney Docket Number	P05691US1

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	51.	US- 5,976,082	11/1999	Wong, et al.	
	52.	US- 5,935,924	8/1999	Bunting, et al.	
	53.	US- 4,196,196	04/1908	Tiholiz	
	54.	US- 5,955,594	09/1999	Mishra	
	55.	US- 6,107,329	08/2000	Hoover et al.	
	56.	US- 6,284,725 B1	09/2001	Coolidge et al.	
		US-			
		US-			
		US-			
		US -			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	57.	WO 95/31214	November/1995	Dupre, John		
	58.	WO 99/40788	August 1999	Young, Andrew A.		
	59.	WO 98/08531	March 1998	Suad, Efendic		
	60.	WO 94/15925	July 1994	Monsanto Company		
	61.	WO 98/08531	March 1998	Eli Lilly & Co.		
	62.	WO 98/08873		Eli Lilly & Co.	(No copy available)	


Examiner Signature		Date Considered	10/28/02
-----------------------	--	--------------------	----------

\*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	09/982,978
		Filing Date	October 22, 2001
		First Named Inventor	Thomas Coolidge
		Group Art Unit	
		Examiner Name	
Sheet 7 of 7	Attorney Docket Number	P05691US1	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	63.	RAUL GARCIA-RINALDI, MD, ERNESTO R. SOLTERO, MD, JORGE CARBALLIDO, MD, JOAQUIN MOJICA, MD, JUAN GONZALEZ-CRUZ, MD., OCTAVIO COSME, MD, and DONALD H GLAESER, D.SC.; D"Left Ventricular Volume Reduction and Reconstruction in Ischemic Cardiomyopathy"; <u>Journal of Cardiac Surgery</u> ; May-June, 1999, vol. 14, No. 3, pp. 199-210; Futura Publishing Company, Inc., Armonk, NY	
	64.	C. ANAGNOSTOPOULOS and S.R. UNDERWOOD; "The detection of myocardial viability and hibernation"; <u>Nuclear Medicine</u> , January 2000, Vol. 21, No. 1, pp. 1-6; Lippincott Williams & Wilkins	
	65.	Penelope R. Sensky, MRCP, Asvina Jivan, PHD, Norah M. Hudson, FRCR, Richard P. Keal, FRCR, Julia L. Tranter, RGN, David de Bono, FRCP, Nilesh J. Samani, FRCP, Graham R. Cherryman, FRCR; "Coronary Artery Disease: Combined Stress MR Imaging Protocol-One-Stop Evaluation of Myocardial Perfusion and Function; 2000, <u>Radiology</u> , pp. 608-614	
	66.	Hiroyuki Yamagishi, M.D. Kaname, Akioka, M.D. Kumiko Hirata, MD, Yuji, Sakanoue, MD, Iku Toda, MD, Minoru Yoshiyama, MD, Masakazu Teragaki, MD, Kazuhide Takeuchi, MD, Junichi Yoshikawa MD, Hironobu Ochi, MD, "Detection of a biphasic Response of Hibernating Myocardium by - Dobutamine-Stress Electrocardiography-Gated Technetium-99m-Tetrofosmin Single Photon Emission Computed Tomography"; 1999, <u>Japanese Circulation Journal</u> , Vol. 63, pp. 688-691	
	67.	E. Barnes, P.G. Camici, "Prevalence of hibernating myocardium in patients with severely impaired ischaemic left ventricles"; <u>Heart</u> , 1999, vol. 82, No. 4, pp 535.	

Examiner Signature		Date Considered	not 10/28/02
--------------------	--	-----------------	--------------

\* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.